Literature DB >> 19474479

CD4+ T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4+ T-cell counts >200 cells/mm3.

Marguerite Guiguet1, Eric Kendjo, Guislaine Carcelain, Sophie Abgrall, Murielle Mary-Krause, Pierre Tattevin, Yazdan Yazdanpanah, Dominique Costagliola, Xavier Duval.   

Abstract

BACKGROUND: The aim of this study was to evaluate the clinical prognostic value of the CD4+ T-cell percentage (%CD4), the CD4+/CD8+ T-cell ratio or the CD8+ T-cell count, in addition to the CD4+ T-cell count and viral load (VL) in antiretroviral-naive HIV-infected patients with CD4+ T-cell counts >200 cells/mm(3).
METHODS: Antiretroviral-naive patients (n=9,740) who were AIDS-free and had a CD4+ T-cell count >200 cells/mm(3) at their first visit after January 1997 were followed-up until treatment initiation or clinical progression (mean follow-up 17 months and 13,660 person-years). Poisson regression was used for statistical analyses.
RESULTS: Progression to AIDS-defining events (ADEs), serious ADEs and death occurred in 228 patients (crude rate 1.69 per 100 person-years), 105 patients (0.77 per 100 person-years) and 67 patients (0.49 per 100 person-years), respectively. Regarding progression to ADE, the data fit was improved when the model also included the %CD4 (Akaike's information criteria [AIC] 2,049) and, to a lesser extent, the CD4+/CD8+ T-cell ratio (AIC 2,053), in addition to CD4+ T-cell count and VL (AIC 2,056). After adjustment for VL and baseline characteristics, patients with CD4+ T-cell counts of 350-500 cells/mm(3) and %CD4<15% had an estimated incidence of ADE of 3 per 100 person-years, similar to that in patients with CD4+ T-cell counts of 200-350 cells/mm(3) and %CD4>15%. The %CD4 was also significantly associated with the risk of serious ADE. By contrast, %CD4, CD4+/CD8+ T-cell ratio or CD8+ T-cell count had no additional prognostic value for the risk of death.
CONCLUSIONS: In antiretroviral-naive HIV-infected patients with CD4+ T-cell counts >200 cells/mm(3), the %CD4 was predictive of the risk of clinical progression independently of CD4+ T-cell count and VL.

Entities:  

Mesh:

Year:  2009        PMID: 19474479     DOI: 10.1177/135965350901400311

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  8 in total

1.  Incidence rate of Kaposi sarcoma in HIV-infected patients on antiretroviral therapy in Southern Africa: a prospective multicohort study.

Authors:  Eliane Rohner; Fabio Valeri; Mhairi Maskew; Hans Prozesky; Helena Rabie; Daniela Garone; Diana Dickinson; Cleophas Chimbetete; Priscilla Lumano-Mulenga; Izukanji Sikazwe; Natascha Wyss; Kerri M Clough-Gorr; Matthias Egger; Benjamin H Chi; Julia Bohlius
Journal:  J Acquir Immune Defic Syndr       Date:  2014-12-15       Impact factor: 3.731

2.  A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication.

Authors:  Matteo Vassallo; R Fabre; J Durant; C Lebrun-Frenay; H Joly; M Ticchioni; F DeSalvador; A Harvey-Langton; B Dunais; M Laffon; J Cottalorda; P Dellamonica; C Pradier
Journal:  J Neurovirol       Date:  2016-11-04       Impact factor: 2.643

3.  Discordance between CD4+ T-lymphocyte counts and percentages in HIV-infected persons with liver fibrosis.

Authors:  Cassidy W Claassen; Marie Diener-West; Shruti H Mehta; David L Thomas; Gregory D Kirk
Journal:  Clin Infect Dis       Date:  2012-03-28       Impact factor: 9.079

4.  CD4/CD8 ratio normalization rates and low ratio as prognostic marker for non-AIDS defining events among long-term virologically suppressed people living with HIV.

Authors:  Win Min Han; Tanakorn Apornpong; Stephen J Kerr; Akarin Hiransuthikul; Sivaporn Gatechompol; Tanya Do; Kiat Ruxrungtham; Anchalee Avihingsanon
Journal:  AIDS Res Ther       Date:  2018-09-27       Impact factor: 2.250

5.  The Impact of Absolute CD4 Count and Percentage Discordance on Pneumocystis Jirovecii Pneumonia Prophylaxis in HIV-Infected Patients.

Authors:  Henry Anyimadu; Chandra Pingili; Vel Sivapalan; Yael Hirsch-Moverman; Sharon Mannheimer
Journal:  J Int Assoc Provid AIDS Care       Date:  2018 Jan-Dec

6.  Comparison of two methodologies for CD4⁺ T lymphocytes relative counting on immune monitoring of patients with human immunodeficiency virus.

Authors:  Danielle Cristyane Kalva Borato; Emerson Carraro; Sônia Regina Weber Ribas; Carlos Augusto Kalva-Filho; José Carlos Rebuglio Vellosa
Journal:  ScientificWorldJournal       Date:  2012-11-28

7.  Immune recovery markers in a double blind clinical trial comparing dolutegravir and raltegravir based regimens as initial therapy (SPRING-2).

Authors:  Jose-Ramon Blanco; Belen Alejos; Santiago Moreno
Journal:  PLoS One       Date:  2020-01-16       Impact factor: 3.240

8.  CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC).

Authors:  Adam Trickey; Margaret T May; Philipp Schommers; Jan Tate; Suzanne M Ingle; Jodie L Guest; M John Gill; Robert Zangerle; Mike Saag; Peter Reiss; Antonella d'Arminio Monforte; Margaret Johnson; Viviane D Lima; Tim R Sterling; Matthias Cavassini; Linda Wittkop; Dominique Costagliola; Jonathan A C Sterne
Journal:  Clin Infect Dis       Date:  2017-09-15       Impact factor: 9.079

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.